Lexicon Pharmaceuticals, Inc. Forecast, price target & analysts
Lexicon Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation
Lexicon Pharmaceuticals, Inc. Classifications & Recommendation:
Lexicon Pharmaceuticals, Inc. Target price
| Target price | $6.20 |
| Course | $1.68 |
| Price potential |
269.05%
register free of charge
|
| Number of estimates | 5 |
|
5 Analysts have issued a price target Lexicon Pharmaceuticals, Inc. 2025 .
The average Lexicon Pharmaceuticals, Inc. target price is $6.20.
This is
269.05%
register free of charge
$10.00
495.24%
register free of charge
$2.00
19.05%
register free of charge
|
|
| A rating was issued by 6 analysts: 4 Analysts recommend Lexicon Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the Lexicon Pharmaceuticals, Inc. share has an average upside potential 2025 of
269.05%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 1.20 | 27.96 |
| 757.14% | 2,230.23% | |
| EBITDA margin | -14,266.67% | -626.89% |
| 80.09% | 95.61% | |
| Net margin | -16,416.00% | -612.48% |
| 84.95% | 96.27% |
6 Analysts have issued a sales forecast Lexicon Pharmaceuticals, Inc. 2024 . The average Lexicon Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth figures:
2 Analysts have issued an Lexicon Pharmaceuticals, Inc. EBITDA forecast 2024. The average Lexicon Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
6 Lexicon Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Lexicon Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -0.80 | -0.70 |
| 29.03% | 12.50% | |
| P/E ratio | negative | |
| EV/Sales | 12.80 |
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast for earnings per share. The average Lexicon Pharmaceuticals, Inc. <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the Lexicon Pharmaceuticals, Inc. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Lexicon Pharmaceuticals, Inc....
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
